Moors & Cabot Inc. Purchases 5,192 Shares of Kenvue Inc. (NYSE:KVUE)

Moors & Cabot Inc. increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 2.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 183,481 shares of the company’s stock after buying an additional 5,192 shares during the period. Moors & Cabot Inc.’s holdings in Kenvue were worth $3,336,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of KVUE. Manchester Capital Management LLC raised its stake in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the last quarter. Mather Group LLC. acquired a new stake in Kenvue in the first quarter worth $28,000. Riverview Trust Co acquired a new stake in Kenvue in the first quarter worth $33,000. MV Capital Management Inc. grew its holdings in Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after purchasing an additional 642 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in Kenvue in the first quarter worth $33,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.0 %

KVUE opened at $23.38 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The company’s 50-day moving average is $20.52 and its 200 day moving average is $19.85. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.55. The firm has a market capitalization of $44.77 billion, a P/E ratio of 29.97, a PEG ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same period last year, the firm earned $0.32 earnings per share. The firm’s revenue was down .3% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were given a dividend of $0.205 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on KVUE shares. JPMorgan Chase & Co. raised their price target on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. UBS Group raised their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Citigroup reduced their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price objective on shares of Kenvue in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $21.44.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.